Today, no effective treatment for Glioblastoma Multiforme (GBM) exists. Additionally, few Non-Small Cell Lung Cancer (NSCLC) patients respond effectively to chemo- and immunotherapies.
That’s why MTTI is developing 177Lu-EBRGD, a radiotherapeutic targeting αvβ3 overexpressing tumors, binding Evans Blue to DOTA-RGD to prolong circulation and increase tissue residence.
In early clinical trials, EBRGD showed improved diagnostic efficacy vs. NOTA- or DOTA-conjugated RGD, as visualized by Cu64 and Ga68 imaging.
US-based Phase I trials are expected to begin in early 2021.